Polycythemia vera screening

Jump to navigation Jump to search

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera screening

CDC on Polycythemia vera screening

Polycythemia vera screening in the news

Blogs on Polycythemia vera screening

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Screening for polycythemia vera is not a routine clinical practice. However, assessment of a complete blood count (CBC), which is done routinely, usually gives the first indication for the presence of polycythemia vera in a patient.

Screening

There is no role for screening for polycythemia vera. In order to diagnose a suspected case of polycythemia vera, JAK2 mutational analysis can be done from the peripheral blood. Cell-based quantitative assays for JAK2 V617F mutation may be helpful among patients with the following:[1]

The complete blood count (CBC), which includes quantitation of red blood cells, white blood cells, and platelets, is typically done routinely in people, and an elevated hemoglobin is sometimes the first laboratory indication for a diagnosis of polycythemia vera.

References

  1. Tefferi A, Noel P, Hanson CA (2011). "Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology". J Mol Diagn. 13 (5): 461–6. doi:10.1016/j.jmoldx.2011.05.007. PMC 3157620. PMID 21723416.

Template:Hematology


Template:WikiDoc Sources